What is the 13F Pro Quality Score for ATYR?

13F Pro ranks aTYR PHARMA INC (ATYR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ATYR's current score at https://13fpro.ai/research/ATYR (free sign-up required for the full ranking).

Which hedge funds own the most ATYR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ATYR include FMR, FEDERATED HERMES,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ATYR as soon as new 13F filings post.

Where does 13F Pro source ATYR data?

All aTYR PHARMA INC fundamentals and ownership data come directly from SEC EDGAR. aTYR PHARMA INC files with the SEC under CIK 1339970. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ATYR in?

aTYR PHARMA INC (ATYR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ATYR research updated on 13F Pro?

ATYR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

aTYR PHARMA INC(ATYR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1339970 ATYR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $10.5M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ATYR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for aTYR PHARMA INC (ATYR), a Healthcare sector company. ATYR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $10.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), aTYR PHARMA INC reports net income of $-10.8M, free cash flow of $-12.7M. Top institutional holders of ATYR by reported 13-F value include FMR, FEDERATED HERMES,, BlackRock,, based on the most recent SEC filings. ATYR trades on the Nasdaq exchange and files with the SEC under CIK 1339970. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATYR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for aTYR PHARMA INC directly from SEC EDGAR.

Net Income

Q1 2026

$-10.8M

Free Cash Flow

Q1 2026

$-12.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-19.1% YoY

$190.0KFY 2025

FY22 $10.4MFY23 $353.0KFY24 $235.0KFY25 $190.0K

Net Income

-15.8% YoY

$-74.1MFY 2025

FY22 $-45.3MFY23 $-50.4MFY24 $-64.0MFY25 $-74.1M

Operating Income

-14.3% YoY

$-77.6MFY 2025

FY22 $-46.4MFY23 $-54.9MFY24 $-67.9MFY25 $-77.6M

EPS (Diluted)

+7.0% YoY

$-0.80FY 2025

FY22 $-1.60FY23 $-0.94FY24 $-0.86FY25 $-0.80

Total Assets

-4.0% YoY

$93.0MFY 2025

FY22 $95.8MFY23 $120.7MFY24 $96.8MFY25 $93.0M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+10.3% YoY

$-62.0MFY 2025

FY22 $-41.9MFY23 $-33.2MFY24 $-69.1MFY25 $-62.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Revenue	$190.0K -19.1%	$235.0K -33.4%	$353.0K -96.6%	$10.4M	$0.00 -100.0%	$422.0K
Net Income	$-74.1M -15.8%	$-64.0M -27.1%	$-50.4M -11.1%	$-45.3M -34.3%	$-33.8M -108.1%	$-16.2M
Operating Income	$-77.6M -14.3%	$-67.9M -23.7%	$-54.9M -18.3%	$-46.4M -36.4%	$-34.0M -48.0%	$-23.0M
EPS (Diluted)	$-0.80 +7.0%	$-0.86 +8.5%	$-0.94 +41.3%	$-1.60 +9.6%	$-1.77	—
Total Assets	$93.0M -4.0%	$96.8M -19.7%	$120.7M +26.0%	$95.8M -17.1%	$115.5M +219.3%	$36.2M
Total Debt	—	—	—	—	—	$8.7M
Operating Cash Flow	$-62.0M +10.3%	$-69.1M -108.1%	$-33.2M +20.7%	$-41.9M -26.6%	$-33.1M -65.3%	$-20.0M

AI Insight: ATYR Financial Trends

Pre-revenue biotech burning cash consistently with no commercialization in sight; equity base eroding quarterly.

• Zero revenue across all periods; company remains entirely pre-commercial with no product launches evident.

• Operating losses stable at $11M–$27M per quarter; Q1 2026 shows modest $11M op loss, best in recent quarters.

• Equity declined from $82M (Q2 2024) to $58M (Q1 2026), a 29% contraction driven by cumulative net losses.

⚠ Operating cash burn averaged $15M/quarter; runway visibility depends on cash reserves not shown in table.

⚠ Q3 2025 peak net loss of $26M suggests elevated R&D spend; sustainability of current burn rate unclear.

AI Insight: ATYR Ratio Trends

aTYR remains deeply unprofitable with no clear path to positive returns; Q1 2026 shows modest improvement in losses but profitability remains years away.

• ROE improved from -128.3% (Q3 2025) to -74.5% (Q1 2026); ROA similarly improved from -96.5% to -54.2%.

• ROIC moved from -90.4% (Q4 2024) to -79.0% (Q1 2026), indicating persistent capital destruction across the period.

⚠ Operating margins, NPM, and D/E ratios unavailable; cash burn trajectory and debt levels cannot be assessed from available data.

⚠ Q3 2025 marked a trough (-128.3% ROE, -96.5% ROA); recovery has begun but company remains loss-making with no visible inflection.

Get alerted when ATYR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for aTYR PHARMA INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ATYR

FMR LLC
$11.5M14,706,843 sh
FEDERATED HERMES, INC.
$8.2M10,509,678 sh
BlackRock, Inc.
$5.0M6,443,904 sh
UBS Group AG
$3.0M3,867,213 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.0M3,812,132 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.9M2,385,485 sh
STATE STREET CORP
$1.4M1,754,399 sh
MILLENNIUM MANAGEMENT LLC
$1.3M1,641,246 sh
MORGAN STANLEY
$955.9K1,225,467 sh
TWO SIGMA INVESTMENTS, LP
$892.8K1,144,565 sh

Fund	Value	Shares
FMR LLC	$11.5M	14,706,843
FEDERATED HERMES, INC.	$8.2M	10,509,678
BlackRock, Inc.	$5.0M	6,443,904
UBS Group AG	$3.0M	3,867,213
VANGUARD CAPITAL MANAGEMENT LLC	$3.0M	3,812,132
GEODE CAPITAL MANAGEMENT, LLC	$1.9M	2,385,485
STATE STREET CORP	$1.4M	1,754,399
MILLENNIUM MANAGEMENT LLC	$1.3M	1,641,246
MORGAN STANLEY	$955.9K	1,225,467
TWO SIGMA INVESTMENTS, LP	$892.8K	1,144,565

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ATYR on your watchlist

Track score changes the day aTYR PHARMA INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ATYR a good stock to buy?

13F Pro's AI-powered analysis of aTYR PHARMA INC (ATYR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ATYR are available on the ATYR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ATYR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ATYR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of aTYR PHARMA INC's investment landscape.